Lonza has revealed a profit hike for the full year of 2007,
reflecting the fruit of its "revised growth strategies"
across its business units, said the firm, which also announced its
"innovations" for future growth...
Product recalls in the UK due to health and safety concerns have
shot up to their highest level, with the rise in outsourcing to
China finger pointed for much of the blame.
Chemical and intermediates firm Lanxess has announced that its
subsidiary Saltigo is the proud new owner of a site in Washington
in the US, formerly used by Eli Lilly subsidiary, ICOS.
Japan's number two pharma firm has elected to set up significant
operations in India - the first Japanese pharma company planning to
plant itself in the country on such a scale.
Roche today announced a handful of new charitable technology
transfer agreements with manufacturers in Africa and Asia, allowing
local production of generic HIV drugs.
UK-based William Ransom & Son has a shaky future ahead
following a disappointing and unacceptable six-month financial
report, compounded by a suspension of the companys manufacturing
license.
Siegfried has signed a $27.7m contract with Arena Pharmaceuticals
to manufacture Arena's Phase III oral obesity drug candidate
lorcaserin hydrochloride.
Patheon has finally revealed its plans to tackle the ongoing
problems it has been facing with its Puerto Rican operations, which
are draining the firm of profitability.
The first steps in tightening the safety controls on the
pharmaceutical ingredients imported to the US from China have been
taken following months of negotiations between the regulatory
bodies of the two countries.
UK-based William Ransom & Son has been advised to voluntarily
recall certain products following a false contamination scare at
its Witham, Essex, facility.
Bristol-Myers Squibb (BMS) has finally detailed its plans to trim
the fat and save cash, months after first revealing that big
changes would be on the cards.
Recipharm has come to rescue of UK-based Ashton Pharma, which has
been nervously awaiting to discover its fate, having spent five
months in administration after its former owners Inyx Inc. suffered
major financial woes.
Pfizer's revelation this week that it plans to slice jobs in Puerto
Rico is the latest in a string of blows for this popular offshore
manufacturing location.
The US Food and Drug Administration (FDA) has given stakeholders an
extra month to get their views in on scrapping epinephrine inhalers
containing CFCs.
Pfizer yesterday announced a multi-million dollar pay-off to
ex-partner Nektar Therapeutics, but the details of the deal reveal
not only Nektar's concerns for its future, but also that Pfizer is
still keeping its fingers in the...
AstraZeneca's axe has made its latest appearance in South Africa,
with the sale of a packaging plant and the formation of an
outsourcing deal with its new owners.
A new report highlights a number of worrying trends emerging in
regard to the increasing number of fake pharmaceuticals
infiltrating supply chains around the globe.
There are lessons to be learned about the importance of rigorous due diligence of pharma contractors, now that Inyx' customers are facing possible supply issues and a scramble to find alternative manufacturers after the firm's collapse.
Swiss pharma Novartis today announced the largest manufacturing investment in its history, revealing plans for a $700m (€486.5m) biotech facility to be built alongside its new solid dose plant in the low cost, high quality biopharma hub of Singapore.
GlaxoSmithKline (GSK) is planning to strip itself down closer to
the bare bones of the business through further outsourcing and
offshoring, with hopes of making itself into a lean, mean, pharma
machine.
Sigma-Aldrich continued its strong year with both revenues and
pre-tax profits showing strong double-digit growth in the third
quarter predicting it will break the $2bn (€1.4bn) revenue mark
this year.
We've all cringed at stories of people dumping their partners via
text message but in the world of business, Pfizer seems to have
taken things to a new level when its Exubera partners were
allegedly left to find out the product...
Growing demand has prompted tableting specialist Meldex
International, formerly BioProgress, to launch a new sales and
distribution hub in Germany, with the UK firm also announcing a new
manufacturing contract for its XGel film.
Catalent Pharma Solutions, the firm born from the spin out of
Cardinal Health's contract manufacturing business, is reorganising
its production facilities with an expansion of its UK site and the
divestiture of some of its French...
Britain's Eden Biodesign has been selected by Cancer Research UK as
the beneficiary of two new biomanufacturing contracts as its
biomanufacturing business continues to grow.
Acambis has had its smallpox vaccine approved by the US, coming one
step closer to closing another supply contract for the US Strategic
National Stockpile.
In the latest phase of growth at chemical firm SAFC's flagship high
potency active pharmaceutical ingredients (HPAPIs) facility in
Madison, Wisconsin, the site will be treated to another
multi-million dollar expansion and new...
Lonza's $200m (€147m) investment in China is continuing to shape up
as the firm announced its new small-scale exclusive synthesis
manufacturing plant will be up and running next month.
ALK-Abello will be funding a new DKK 300m (€40.3m) production line
dedicated to its oral grass pollen allergy vaccine at Catalent
Pharma Solutions' UK facility.
GlaxoSmithKline (GSK) and Merck Sharp & Dohme (MSD) have made
further moves in their plans to boost their presence in Singapore,
a region growing in popularity for biopharmaceutical research and
manufacture.
The Medical House (TMH) has sold its SQ-PEN needle-free insulin
injector business as it moves away from supplying the product to
private individuals to focus more on its drug delivery systems
business.
Pharmaceutical packaging and processing machinery specialist IMA
has announced its half year results, with its active expansion
plans paying dividends and its pharma business going strong.
UK Hikma Pharmaceuticals has acquired Egyptian pharmaceutical
company Alkan Pharma in a deal worth $60.5m (€44.2m), and
establishes the London-based company in the Egyptian market.
China has announced an initial $1.7bn investment to bolster its
currently questionable ability to effectively monitor the quality
of the food and drugs manufactured within its borders.
A US bankruptcy court judge ruled on Friday that Puerto Rican-based
pharma services firm Inyx USA be put under the control of an
independently-appointed trustee.
